Abu Dhabi, United Arab Emirates: Hayat Biotech, a leading UAE-based biotech company, has invited national and international healthcare experts, renowned academics, and representatives from Abu Dhabi’s Department of Health (DoH) to discuss the future of the UAE’s healthcare system and Abu Dhabi’s role in Darbi on the international stage. The panel discussion, titled Abu Dhabi Life Science Revolution, was held at Khalifa University, Hayat Biotech’s main strategic partner in R&D, career advancement and human capital development.
In line with DoH’s mission to be a global hub for life science research and innovation, and following the signing of a partnership statement between DoH and Hayat Biotech in January 2023, the discussion group facilitated the exchange of knowledge and experience, and explored priorities and key points for life science research Domain activation and collaboration.
The event began with a welcome address from Naser Al Yammahi, Deputy CEO of Hayat Biotech.
Moderated by Mustafa Al Rawi, Acting Managing Director, CNN Business Arabic, Dr. Dirk Kuhlmeier, Co-Founder, Fraunhofer Project Center; Dr. Nawal Al Kaabi, Senior Advisor, Haya Biotech; Dirk Richter, Director of Health Sector Innovation, Abu Dhabi Department of Health (DoH) Dr. Yunli Zhao, Vice President Production, Hayat Biotech; Dr. Mira Mousa, Deputy Director, Biomedical Science Discovery Program, Khalifa University, shared their thoughts on the role of clinical trials, the importance of R&D, and the UAE’s growing manufacturing capabilities, This will position Abu Dhabi and the MENA region as a leading player in the global life sciences industry.
With a combined annual production capacity of 230 million vials, Hayat Biotech’s cutting-edge biotech facilities in Abu Dhabi and Belgrade, Serbia play a vital role in the company’s global ambitions. By attracting international companies to move production to these facilities, Hayat Biotech has successfully forged partnerships and positioned itself as the destination of choice for biopharmaceutical companies seeking to establish local and regional manufacturing capabilities in the UAE.
Following the discussions, the senior leadership of the Fraunhofer Institute and Hayat Biotech held additional conversations to explore the potential for collaboration in clinical trials, diagnostics and vaccine production.
Due to its strategic location, Abu Dhabi acts as a safe and efficient gateway for global distribution, especially in the healthcare industry. UAE authorities have taken proactive steps to implement diverse programs and initiatives to create an attractive environment for international businesses in the region. With its notable advancements in healthcare, the UAE has strengthened its position as an important hub for the logistics, transportation and distribution of medicines, playing an active role in improving global health.
Hayat Biotech, in partnership with IROS, has become the healthcare industry’s preferred partner for clinical research due to its expertise and continued commitment to conducting clinical trials. In addition to the eight clinical trials already underway in the UAE, Hayat Biotech is continuously developing new innovative biopharmaceutical products to address unmet medical needs or improve existing treatments. The company’s dedication to medical science makes it a trusted partner for biopharmaceutical companies looking to conduct clinical research and bring new products to market.
Naser Al Yammahi, Deputy Chief Executive Officer, Hayat Biotech said: “This discussion panel provides a unique opportunity to engage in exciting dialogues with nationally and internationally renowned experts. Distinguished speakers, industry leaders, renowned academics and Hayat Biotech senior tubes to share their expertise and discuss the transformative impact of companies’ contributions to the healthcare ecosystem.We are passionately committed to supporting the Ministry of Health’s ambition to establish Abu Dhabi as a global center of excellence for biotechnology and life sciences vision. To realize this vision, we will leverage our cutting-edge expertise in biopharmaceuticals and will leverage Hayat Biotech’s advanced manufacturing capabilities. We are firmly committed to partnering with international pharmaceutical companies to facilitate their production locally and help them achieve their growth goals. Our ultimate goal is to have a lasting impact on the industry globally, changing the biotech and life sciences landscape for generations to come.”
Emphasizing the importance of clinical trials in the life science industry, Dr. Nawal Al Kaabi, Senior Consultant at Hayat Biotech, said: R&D. Conducting clinical trials in Abu Dhabi provides access to diverse patient populations that may not be available in other regions. This diversity is critical for testing the efficacy and safety of drugs in populations of different races and health conditions, which can lead to more accurate results and better treatments.
“Our collaboration with the Abu Dhabi Department of Health has been very successful and we are working to expand the collaboration further with the goal of delivering new and innovative treatments both nationally and internationally.”
Hayat Biotech’s commitment to transforming the healthcare industry through innovative solutions and partnerships with local and global stakeholders is evident. As Abu Dhabi continues to establish itself as a leading center for biopharmaceutical research, development and production, Hayat Biotech plays a key role in driving this advancement. With cutting-edge facilities and a dedicated team of experts, the company is well-positioned to have a significant impact on the global life sciences industry.